格非他单抗致细胞因子持续释放综合征1例报告并文献复习。

IF 3.1 Q2 PHARMACOLOGY & PHARMACY

Clinical Pharmacology : Advances and Applications Pub Date : 2025-04-29 eCollection Date: 2025-01-01 DOI:10.2147/CPAA.S515122

Jingyi Yang, Qian Shen, Xiaoyan Ke, Wei Liu, Ping Yang

{"title":"格非他单抗致细胞因子持续释放综合征1例报告并文献复习。","authors":"Jingyi Yang, Qian Shen, Xiaoyan Ke, Wei Liu, Ping Yang","doi":"10.2147/CPAA.S515122","DOIUrl":null,"url":null,"abstract":"Glofitamab is a novel bispecific antibody targeting CD20×CD3, capable of simultaneously targeting CD20 and CD3 to activate T cells and release cytotoxic proteins that kill cancer cells. Cytokine release syndrome (CRS) is one of the most common adverse events observed in clinical trials of glofitamab. In most cases, CRS is mild, transient, and manageable with appropriate treatment. This paper reports a case of persistent CRS in a patient with mantle cell lymphoma following glofitamab treatment and reviews the relevant literature for reference.","PeriodicalId":10406,"journal":{"name":"Clinical Pharmacology : Advances and Applications","volume":"17 ","pages":"79-83"},"PeriodicalIF":3.1000,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12049670/pdf/","citationCount":"0","resultStr":"{\"title\":\"A Case Report of Sustained Cytokine Release Syndrome Due to Glofitamab and Literature Review.\",\"authors\":\"Jingyi Yang, Qian Shen, Xiaoyan Ke, Wei Liu, Ping Yang\",\"doi\":\"10.2147/CPAA.S515122\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Glofitamab is a novel bispecific antibody targeting CD20×CD3, capable of simultaneously targeting CD20 and CD3 to activate T cells and release cytotoxic proteins that kill cancer cells. Cytokine release syndrome (CRS) is one of the most common adverse events observed in clinical trials of glofitamab. In most cases, CRS is mild, transient, and manageable with appropriate treatment. This paper reports a case of persistent CRS in a patient with mantle cell lymphoma following glofitamab treatment and reviews the relevant literature for reference.\",\"PeriodicalId\":10406,\"journal\":{\"name\":\"Clinical Pharmacology : Advances and Applications\",\"volume\":\"17 \",\"pages\":\"79-83\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-04-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12049670/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Pharmacology : Advances and Applications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/CPAA.S515122\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacology : Advances and Applications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/CPAA.S515122","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

Glofitamab是一种新型双特异性抗体，靶向CD20×CD3，能够同时靶向CD20和CD3激活T细胞并释放杀死癌细胞的细胞毒性蛋白。细胞因子释放综合征（CRS）是格非他单抗临床试验中最常见的不良事件之一。在大多数情况下，CRS是轻微的，短暂的，在适当的治疗下是可控的。本文报道一例经格非他单抗治疗的套细胞淋巴瘤患者出现持续性CRS，并复习相关文献以供参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A Case Report of Sustained Cytokine Release Syndrome Due to Glofitamab and Literature Review.

Glofitamab is a novel bispecific antibody targeting CD20×CD3, capable of simultaneously targeting CD20 and CD3 to activate T cells and release cytotoxic proteins that kill cancer cells. Cytokine release syndrome (CRS) is one of the most common adverse events observed in clinical trials of glofitamab. In most cases, CRS is mild, transient, and manageable with appropriate treatment. This paper reports a case of persistent CRS in a patient with mantle cell lymphoma following glofitamab treatment and reviews the relevant literature for reference.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Pharmacology : Advances and Applications PHARMACOLOGY & PHARMACY-

CiteScore

4.60

自引率

0.00%

发文量

审稿时长

16 weeks